Collins Timire1, John Z Metcalfe2, Joconiah Chirenda3, Jerod N Scholten4, Barbara Manyame-Murwira5, Mkhokheli Ngwenya6, Ronnie Matambo7, Kelvin Charambira7, Herbert Mutunzi5, Nico Kalisvaart4, Charles Sandy8. 1. International Union Against Tuberculosis and Lung Disease (The Union), Paris, France; Ministry of Health and Child Care, National TB Control Program, Harare, Zimbabwe. 2. Division of Pulmonary and Critical Care Medicine, Zuckerberg San Francisco General Hospital and Trauma Center, University of California, San Francisco, CA, USA. 3. University of Zimbabwe, College of Health Sciences, Harare, Zimbabwe. 4. KNCV Tuberculosis Foundation, The Hague, The Netherlands. 5. Ministry of Health and Child Care, National TB Control Program, Harare, Zimbabwe. 6. World Health Organisation, Zimbabwe Country Office, Harare, Zimbabwe. 7. The Union, Harare, Zimbabwe. 8. Ministry of Health and Child Care, National TB Control Program, Harare, Zimbabwe. Electronic address: dr.c.sandy@gmail.com.
Abstract
OBJECTIVE: To determine the prevalence of resistance to rifampicin alone; rifampicin and isoniazid, and second-line anti-TB drugs among sputum smear-positive tuberculosis patients in Zimbabwe. DESIGN: A health facility-based cross-sectional survey. RESULTS: In total, 1114 (87.6%) new and 158 (12.4%) retreatment TB patients were enrolled. MTB was confirmed by Xpert MTB/RIF among 1184 (93%) smear-positive sputum samples. There were 64 samples with Xpert MTB/RIF-determined rifampicin resistance. However, two were rifampicin susceptible on phenotypic drug susceptibility testing. The prevalence of RR-TB was [4.0% (95% CI, 2.9, 5.4%), n=42/1043) and 14.2% (95% CI, 8.9, 21.1%; n=20/141) among new and retreatment patients, respectively. The prevalence of MDR-TB was 2.0% (95% CI, 1.3, 3.1%) and 6.4% (95% CI, 2.4, 10.3%) among new and retreatment TB patients, respectively. Risk factors for RR-TB included prior TB treatment, self-reported HIV infection, travel outside Zimbabwe for ≥one month (univariate), and age <15 years. Having at least a secondary education was protective against RR-TB. CONCLUSION: The prevalence of MDR-TB in Zimbabwe has remained stable since the 1994 subnational survey. However, the prevalence of rifampicin mono-resistance was double that of MDR-TB.
OBJECTIVE: To determine the prevalence of resistance to rifampicin alone; rifampicin and isoniazid, and second-line anti-TB drugs among sputum smear-positive tuberculosis patients in Zimbabwe. DESIGN: A health facility-based cross-sectional survey. RESULTS: In total, 1114 (87.6%) new and 158 (12.4%) retreatment TB patients were enrolled. MTB was confirmed by Xpert MTB/RIF among 1184 (93%) smear-positive sputum samples. There were 64 samples with Xpert MTB/RIF-determined rifampicin resistance. However, two were rifampicin susceptible on phenotypic drug susceptibility testing. The prevalence of RR-TB was [4.0% (95% CI, 2.9, 5.4%), n=42/1043) and 14.2% (95% CI, 8.9, 21.1%; n=20/141) among new and retreatment patients, respectively. The prevalence of MDR-TB was 2.0% (95% CI, 1.3, 3.1%) and 6.4% (95% CI, 2.4, 10.3%) among new and retreatment TB patients, respectively. Risk factors for RR-TB included prior TB treatment, self-reported HIV infection, travel outside Zimbabwe for ≥one month (univariate), and age <15 years. Having at least a secondary education was protective against RR-TB. CONCLUSION: The prevalence of MDR-TB in Zimbabwe has remained stable since the 1994 subnational survey. However, the prevalence of rifampicin mono-resistance was double that of MDR-TB.
Authors: H J Menzies; G Moalosi; V Anisimova; V Gammino; C Sentle; M A Bachhuber; E Bile; K Radisowa; O Kachuwaire; J Basotli; T Maribe; R Makombe; J Shepherd; B Kim; T Samandari; S El-Halabi; J Chirenda; K P Cain Journal: Int J Tuberc Lung Dis Date: 2014-09 Impact factor: 2.373
Authors: R Ridzon; C G Whitney; M T McKenna; J P Taylor; S H Ashkar; A T Nitta; S M Harvey; S Valway; C Woodley; R Cooksey; I M Onorato Journal: Am J Respir Crit Care Med Date: 1998-06 Impact factor: 21.405
Authors: Llang B Maama-Maime; Mathabo Mareka; Julia V Ershova; Thabong E Tlali; Kekeletso Kao; Mamakhetha Phalatse; Lauren Polansky; Laura K Beres; Moselinyane Letsie; Timothy H Holtz Journal: PLoS One Date: 2015-07-24 Impact factor: 3.240
Authors: John Z Metcalfe; Salome Makumbirofa; Beauty Makamure; Charles Sandy; Wilbert Bara; Stanley Mungofa; Philip C Hopewell; Peter Mason Journal: Emerg Infect Dis Date: 2014-01 Impact factor: 6.883
Authors: Collins Timire; Mkhokheli Ngwenya; Joconiah Chirenda; John Z Metcalfe; Katharina Kranzer; Debora Pedrazzoli; Kudakwashe C Takarinda; Peter Nguhiu; Geshem Madzingaidzo; Kwenzikweyinkosi Ndlovu; Tawanda Mapuranga; Morna Cornell; Charles Sandy Journal: Trop Med Int Health Date: 2021-08-03 Impact factor: 2.622
Authors: Joseph Baruch Baluku; Pallen Mugabe; Rose Mulwana; Sylvia Nassozi; Richard Katuramu; William Worodria Journal: Biomed Res Int Date: 2020-07-25 Impact factor: 3.411